Austar Lifesciences Limited
AULSF
$0.07
$0.071,300.00%
OTC PK
| 06/30/2025 | 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | |
|---|---|---|---|---|---|
| Revenue | -5.27% | -11.19% | -16.40% | -15.79% | -20.52% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -5.27% | -11.19% | -16.40% | -15.79% | -20.52% |
| Cost of Revenue | -6.58% | -12.35% | -17.43% | -13.24% | -17.19% |
| Gross Profit | 0.27% | -6.28% | -12.06% | -24.86% | -32.13% |
| SG&A Expenses | -11.53% | -21.53% | -29.57% | -22.20% | -18.02% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -53.50% | -85.04% | -128.57% | -97.69% | -41.83% |
| Total Operating Expenses | -8.12% | -14.59% | -20.18% | -15.46% | -17.74% |
| Operating Income | 489.15% | 239.02% | 183.69% | -41.98% | -116.76% |
| Income Before Tax | 324.95% | 218.89% | 161.37% | -95.85% | -130.25% |
| Income Tax Expenses | 169.22% | 331.29% | 1,539.29% | 24.28% | -59.80% |
| Earnings from Continuing Operations | 248.29% | 181.29% | 138.84% | -117.00% | -141.54% |
| Earnings from Discontinued Operations | -- | -- | -- | 58.39% | -42.00% |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -24.48% | -8.33% | 13.23% | 127.24% | 154.19% |
| Net Income | 152.06% | 128.12% | 114.03% | 56.93% | -2,231.76% |
| EBIT | 489.15% | 239.02% | 183.69% | -41.98% | -116.76% |
| EBITDA | 259.36% | 10,757.01% | 426.64% | 5.21% | -73.53% |
| EPS Basic | 152.75% | 128.46% | 114.15% | 57.41% | -2,175.00% |
| Normalized Basic EPS | 300.00% | 206.52% | 156.67% | -94.74% | -135.16% |
| EPS Diluted | 152.17% | 127.94% | 113.50% | 56.17% | -2,200.00% |
| Normalized Diluted EPS | 300.00% | 206.52% | 156.67% | -94.74% | -135.16% |
| Average Basic Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Average Diluted Shares Outstanding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |